Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Syncona Ltd - London-based investor in healthcare companies - Says Syncona Investment Management Ltd has submitted a non-binding proposal to acquire the entire remaining share capital of Freeline Therapeutic Holdings PLC. Offers upfront cash consideration of $5.00 per American depository share, representing a 20% premium over the $4.16 volume weighted average price from October 4 to October 16. Syncona currently owns around 57.9% of shares in Stevenage, England-based Freeline, which it co-founded in 2015. Freeline aims to develop gene therapies to treat chronic diseases, most notably its potentially ‘transformative’ FLT201 programme to treat Gaucher disease.
Current stock price: 126.30 pence, up 0.2% in London on Wednesday around noon
12-month change: down 24%
Copyright 2023 Alliance News Ltd. All Rights Reserved.